With a name anchored in the strong MMQCI Scottish ties, Birlinn (Scottish Gaelic for swift, stalwart Viking ship) controls have a large sequence coverage and work on most platforms and LDTs, reliably guarding your lab's accuracy and providing the best solutions for your Quality Control Program.
Above all, you can still trust that our new controls have the advantages that you have come to expect from MMQCI:
- Reliable: lot to lot consistency tested over multiple sites, instruments, operators, and cartridge lots
- Multiplex: all pathogens detected by the assay are included in only a couple tubes
- Easy to use: no reconstitution, pooling, or dilution needed. Use as provided.
- Safe to handle: does not contain any biological material from human or animal origin
- Versatile: reference material for validation, verification, routine monitoring, and training
Use Birlinn controls to help you create a swift and steadfast Quality Control Program (QCP) to protect your lab’s accuracy, and to assist your team in identifying shifts and trends in your results. Stay on the right track with Birlinn!
Hereditary hemochromatosis is an autosomal recessive iron-storage disorder characterized by inappropriately high absorption of iron, most commonly associated with H63D, S65C and C282Y mutations. The Birlinn™ HH Panel G203 is a non-extractable control with copy numbers of HFE DNA similar to that of extracted human whole blood to mimic a patient sample.
The Philadelphia chromosome, a translocation between the ABL1 gene on chromosome 9 and the BCR gene on chromosome 22, generates the fusion gene BCR-ABL1 which is present in most chronic myelogenous leukemia patients. The Birlinn BCR-ABL1 p210 IS Panel C230, with assigned values traceable to World Health Organization (WHO), allows calculation of a Conversion Factor (CF) necessary to express quantification results according to the International Scale (IS).
Quantitative monitoring of BCR-ABL1 transcripts in patient blood is an important tool for measuring response to therapy. In 2009, the WHO developed a panel of four BCR-ABL1 primary standards to establish a standardized method for reporting assay results as a ratio of fusion transcripts to control gene transcripts (%IS), useful to the harmonization of patient care across laboratories worldwide. The Birlinn BCR-ABL1 p210 IS Control Panel C240, with assigned values traceable to WHO, allows monitoring of assay performance reporting on the IS.
CoV2-Flu-RSV Control
COMING SOON – Expected by end of December 2024